206 related articles for article (PubMed ID: 38392212)
21. Mutant p53: it's not all one and the same.
Kennedy MC; Lowe SW
Cell Death Differ; 2022 May; 29(5):983-987. PubMed ID: 35361963
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
23. Mutant p53 Gain-of-Function Induces Migration and Invasion through Overexpression of miR-182-5p in Cancer Cells.
Madrigal T; Ortega-Bernal D; Herrera LA; González-De la Rosa CH; Domínguez-Gómez G; Aréchaga-Ocampo E; Díaz-Chávez J
Cells; 2023 Oct; 12(20):. PubMed ID: 37887350
[TBL] [Abstract][Full Text] [Related]
24. The rebel angel: mutant p53 as the driving oncogene in breast cancer.
Walerych D; Napoli M; Collavin L; Del Sal G
Carcinogenesis; 2012 Nov; 33(11):2007-17. PubMed ID: 22822097
[TBL] [Abstract][Full Text] [Related]
25. Effect of SUV39H1 Histone Methyltransferase Knockout on Expression of Differentiation-Associated Genes in HaCaT Keratinocytes.
Sobiak B; Leśniak W
Cells; 2020 Dec; 9(12):. PubMed ID: 33297464
[TBL] [Abstract][Full Text] [Related]
26. Triptolide promotes degradation of the unfolded gain-of-function Tp53
Zhou J; Luo J; Li P; Zhou Y; Li P; Wang F; Mallio CA; Rossi G; Jalal AH; Filipovic N; Tian Z; Zhao X
Transl Lung Cancer Res; 2022 May; 11(5):802-816. PubMed ID: 35693277
[TBL] [Abstract][Full Text] [Related]
27. Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones.
Ren YA; Mullany LK; Liu Z; Herron AJ; Wong KK; Richards JS
Cancer Res; 2016 Apr; 76(8):2206-18. PubMed ID: 26964623
[TBL] [Abstract][Full Text] [Related]
28. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
29. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
Pallocca M; Goeman F; De Nicola F; Melucci E; Sperati F; Terrenato I; Pizzuti L; Casini B; Gallo E; Amoreo CA; Vici P; Di Lauro L; Buglioni S; Diodoro MG; Pescarmona E; Mazzotta M; Barba M; Fanciulli M; De Maria R; Ciliberto G; Maugeri-Saccà M
J Transl Med; 2018 Sep; 16(1):247. PubMed ID: 30180862
[TBL] [Abstract][Full Text] [Related]
30. Potential therapeutic targets of
Tanaka T; Watanabe M; Yamashita K
Oncotarget; 2018 Mar; 9(22):16234-16247. PubMed ID: 29662640
[TBL] [Abstract][Full Text] [Related]
31. miR129-1 regulates protein phosphatase 1D protein expression under hypoxic conditions in non-small cell lung cancer cells harboring a TP53 mutation.
Yin HL; Xu HW; Lin QY
Oncol Lett; 2020 Sep; 20(3):2239-2247. PubMed ID: 32782541
[TBL] [Abstract][Full Text] [Related]
32. Genome-Wide Small RNA Sequencing Identifies MicroRNAs Deregulated in Non-Small Cell Lung Carcinoma Harboring Gain-of-Function Mutant p53.
Datta A; Das P; Dey S; Ghuwalewala S; Ghatak D; Alam SK; Chatterjee R; Roychoudhury S
Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31661871
[TBL] [Abstract][Full Text] [Related]
33. Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes.
Chen X; Shen B; Xia L; Khaletzkiy A; Chu D; Wong JY; Li JJ
Cancer Res; 2002 Feb; 62(4):1213-21. PubMed ID: 11861406
[TBL] [Abstract][Full Text] [Related]
34. Mutant p53 in Cancer Progression and Targeted Therapies.
Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
Front Oncol; 2020; 10():595187. PubMed ID: 33240819
[No Abstract] [Full Text] [Related]
35. Mutated p53 in HGSC-From a Common Mutation to a Target for Therapy.
Saleh A; Perets R
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298679
[TBL] [Abstract][Full Text] [Related]
36. Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.
Sasaki K; Takahashi S; Ouchi K; Otsuki Y; Wakayama S; Ishioka C
Sci Rep; 2023 Mar; 13(1):4868. PubMed ID: 36964217
[TBL] [Abstract][Full Text] [Related]
37.
Coan M; Toso M; Cesaratto L; Rigo I; Borgna S; Dalla Pietà A; Zandonà L; Iuri L; Zucchetto A; Piazza C; Baldassarre G; Spizzo R; Nicoloso MS
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762037
[No Abstract] [Full Text] [Related]
38. [Cross-talk between nuclear factor-kappaB and P53 signal pathway in keratinocytes after ultraviolet B irradiation].
Wang P; Song XZ; Bi ZG; Xu AE; Cui YG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3088-91. PubMed ID: 18261359
[TBL] [Abstract][Full Text] [Related]
39. CRISPR-assisted receptor deletion reveals distinct roles for ERBB2 and ERBB3 in skin keratinocytes.
Dahlhoff M; Gaborit N; Bultmann S; Leonhardt H; Yarden Y; Schneider MR
FEBS J; 2017 Oct; 284(19):3339-3349. PubMed ID: 28805349
[TBL] [Abstract][Full Text] [Related]
40. Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression.
Vinall RL; Chen JQ; Hubbard NE; Sulaimon SS; Shen MM; Devere White RW; Borowsky AD
Dis Model Mech; 2012 Nov; 5(6):914-20. PubMed ID: 22563073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
